2021 CMSC Annual Meeting

Tag: 7270DMT34Poster-Disease-modifying TherapyJacob A Sloane

Poster-Disease-modifying Therapy

Treatment Persistence, Safety, Tolerability, and Effectiveness of Diroximel Fumarate in the Real-World: Design of the Phase 4 Experience–US Study

Background: Diroximel fumarate (DRF) is an oral fumarate approved in the United States (US) for relapsing multiple sclerosis (MS). DRF...

Read More